Ellagic acid reduces methotrexate-induced apoptosis and mitochondrial dysfunction via up-regulating Nrf2 expression and inhibiting the IĸBα/NFĸB in rats
- 56 Downloads
The clinical application of methotrexate (MTX), an efficacious cytotoxic drug, is restricted due to its associated liver toxicity. Ellagic acid (EA), a natural polyphenol, possesses hepatoprotective, antioxidant and anti-inflammatory properties.
The present study seeks to address the hepatoprotective effects of Ellagic acid (EA) against MTX-mediated oxidative stress (OS) and widen our current knowledge of the underlying molecular mechanisms of MTX toxicity.
Wistar rats were orally given EA (5 mg/kg and 10 mg/kg) for 10 successive days and at the end of the third day they were administered a single dose of MTX (20 mg/kg i.p).
After performing biochemical analysis, liver enzymes and malondialdehyde were significantly higher in the MTX group, indicating hepatic oxidative damage. MTX-induced OS was further confirmed with observation of events such as reactive oxygen species (ROS) overproduction, mitochondrial outer membrane potential decrease, mitochondrial swelling, cytochrome c release and caspase-3/9 increase, resulting in apoptosis. Furthermore, overexpression of pro-inflammatory factors such as nuclear factor kappa B (NF-ĸB) and interleukin 6 (IL-6) indicated the MTX-induced inflammation in MTX-treated group. Interestingly, EA was able to significantly prevent OS, mitochondrial dysfunction, apoptosis and inflammation induced by MTX. Also, EA-treated rats demonstrated significant upregulation of both nuclear factor erythroid 2-related factor 2 (Nrf2) and hemoxygenase-1 (HO-1), which were considerably downregulated in MTX-treated rats.
EA protects rats against MTX-induced apoptosis and mitochondrial dysfunction via up-Regulating Nrf2 and HO-1 expression and inhibiting the NF-κB signaling pathway. Therefore, EA may protect patients against MTX-induced hepatotoxicity and encourage its clinical application.
KeywordsEllagic acid Mitochondrial dysfunction Oxidative stress Inflammation Apoptosis
This work was supported by Vice Chancellor for Research, Tehran University of Medical Sciences, Tehran, Iran under Grant (96-03-169-36364).
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest regarding the publication of this article.
- 1.Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–82. https://doi.org/10.1016/S0140-6736(08)61000-4.CrossRefPubMedGoogle Scholar
- 7.Paul M, Hemshekhar M, Thushara RM, Sundaram MS, NaveenKumar SK, Naveen S, et al. Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-Acetylcysteine and N-Acetylcysteine amide. PLoS One. 2015;10(6):e0127558. https://doi.org/10.1371/journal.pone.0127558.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Mahmoud AM, Hussein OE, Hozayen WG, Abd El-Twab SM. Methotrexate hepatotoxicity is associated with oxidative stress, and down-regulation of PPARgamma and Nrf2: protective effect of 18beta-Glycyrrhetinic acid. Chem Biol Interact. 2017;270:59–72. https://doi.org/10.1016/j.cbi.2017.04.009.CrossRefPubMedGoogle Scholar
- 11.Oveissi V, Ram M, Bahramsoltani R, Ebrahimi F, Rahimi R, Naseri R, et al. Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective. Daru. 2019;27:389–406. https://doi.org/10.1007/s40199-019-00255-6.CrossRefPubMedGoogle Scholar
- 12.Bahramsoltani R, Ebrahimi F, Farzaei MH, Baratpourmoghaddam A, Ahmadi P, Rostamiasrabadi P, et al. Dietary polyphenols for atherosclerosis: a comprehensive review and future perspectives. Crit Rev Food Sci Nutr. 2019;59(1):114–32. https://doi.org/10.1080/10408398.2017.1360244.CrossRefPubMedGoogle Scholar
- 14.Hseu YC, Chou CW, Senthil Kumar KJ, Fu KT, Wang HM, Hsu LS, et al. Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem Toxicol. 2012;50(5):1245–55. https://doi.org/10.1016/j.fct.2012.02.020.CrossRefPubMedGoogle Scholar
- 15.Mukherjee S, Ghosh S, Choudhury S, Adhikary A, Manna K, Dey S, et al. Pomegranate reverses methotrexate-induced oxidative stress and apoptosis in hepatocytes by modulating Nrf2-NF-kappaB pathways. J Nutr Biochem. 2013;24(12):2040–50. https://doi.org/10.1016/j.jnutbio.2013.07.005.CrossRefPubMedGoogle Scholar
- 18.Bodaghi-Namileh V, Sepand MR, Omidi A, Aghsami M, Seyednejad SA, Kasirzadeh S, et al. Acetyl-l-carnitine attenuates arsenic-induced liver injury by abrogation of mitochondrial dysfunction, inflammation, and apoptosis in rats. Environ Toxicol Pharmacol. 2018;58:11–20. https://doi.org/10.1016/j.etap.2017.12.005.CrossRefPubMedGoogle Scholar
- 20.Sepand MR, Ghahremani MH, Razavi-Azarkhiavi K, Aghsami M, Rajabi J, Keshavarz-Bahaghighat H, et al. Ellagic acid confers protection against gentamicin-induced oxidative damage, mitochondrial dysfunction and apoptosis-related nephrotoxicity. J Pharm Pharmacol. 2016;68(9):1222–32. https://doi.org/10.1111/jphp.12589.CrossRefPubMedGoogle Scholar
- 27.Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol. 2009;23(6):735–45. https://doi.org/10.1111/j.1472-8206.2009.00722.x.CrossRefPubMedGoogle Scholar
- 29.Aghsami M, Sharifzadeh M, Sepand MR, Yazdankhah M, Seyednejad SA, Pourahmad J. A cAMP analog attenuates beta-amyloid (1-42)-induced mitochondrial dysfunction and spatial learning and memory deficits. Brain Res Bull. 2018;140:34–42. https://doi.org/10.1016/j.brainresbull.2018.03.016.CrossRefPubMedGoogle Scholar
- 34.Keshavarz-Bahaghighat H, Sepand MR, Ghahremani MH, Aghsami M, Sanadgol N, Omidi A, et al. Acetyl-L-Carnitine attenuates arsenic-induced oxidative stress and hippocampal mitochondrial dysfunction. Biol Trace Elem Res. 2018;184(2):422–35. https://doi.org/10.1007/s12011-017-1210-0.CrossRefPubMedGoogle Scholar
- 40.Abdo S, Zhang SL, Chan JS. Reactive oxygen species and nuclear factor Erythroid 2-related factor 2 activation in diabetic nephropathy: a hidden target. J Diabetes Metab. 2015;6(6). https://doi.org/10.4172/2155-6156.1000547.
- 42.Sheibani M, Faghir-Ghanesefat H, Dehpour S, Keshavarz-Bahaghighat H, Sepand MR, Ghahremani MH, et al. Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. Inflammopharmacology. 2019;27:1071–80. https://doi.org/10.1007/s10787-019-00586-5.CrossRefPubMedGoogle Scholar
- 45.Jun CD, Kim Y, Choi EY, Kim M, Park B, Youn B, et al. Gliotoxin reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice: evidence of the connection between heme oxygenase-1 and the nuclear factor-kappaB pathway in vitro and in vivo. Inflamm Bowel Dis. 2006;12(7):619–29. https://doi.org/10.1097/01.ibd.0000225340.99108.8a.CrossRefPubMedGoogle Scholar
- 46.Yeh PY, Li CY, Hsieh CW, Yang YC, Yang PM, Wung BS. CO-releasing molecules and increased heme oxygenase-1 induce protein S-glutathionylation to modulate NF-kappaB activity in endothelial cells. Free Radic Biol Med. 2014;70:1–13. https://doi.org/10.1016/j.freeradbiomed.2014.01.042.CrossRefPubMedGoogle Scholar
- 47.Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A. 1994;91(13):5987–91. https://doi.org/10.1073/pnas.91.13.5987.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol. 2006;69(3):1033–40. https://doi.org/10.1124/mol.105.018374.CrossRefPubMedGoogle Scholar